Present status and perspective of pharmacogenetics in Mexico

Drug Metabolism and Drug Interactions

Volumn 29, Issue 1, 2014, Pages 37-45

  Cuautle Rodríguez, Patricia ^a   Llerena, Adrián ^b   Molina Guarneros, Juan ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Cytochrome P450; Drug metabolizing enzymes; Interindividual variability; Pharmacogenetics; Phenotyping cocktails

Indexed keywords

CAFFEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; LOSARTAN; N ACYLTRANSFERASE 2 PROTEIN; OMEPRAZOLE; PROTEIN; UNCLASSIFIED DRUG;

BIOTRANSFORMATION; CLINICAL RESEARCH; DRUG COST; DRUG METABOLISM; DRUG RESPONSE; ENZYME POLYMORPHISM; GENOTYPE; HUMAN; META ANALYSIS (TOPIC); MEXICO; MORBIDITY; MORTALITY; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; REVIEW; SAFETY;

ARYLAMINE N-ACETYLTRANSFERASE; BIOMEDICAL RESEARCH; CYTOCHROME P-450 ENZYME SYSTEM; DRUG COMBINATIONS; DRUG COSTS; GENOTYPE; GLUTATHIONE TRANSFERASE; GLYCOSYLTRANSFERASES; HETEROZYGOTE; HUMANS; INDIVIDUALIZED MEDICINE; MEXICAN AMERICANS; MEXICO; PHARMACOGENETICS; PHENOTYPE;

EID: 84896782635     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2013-0019     Document Type: Review

References (40)

1. Dirección General de Información en salud (DGIS). Base de datos de defunciones generales 1979-2007. Sistema Nacional de Salud (SINAIS). Available at: http://www.sinais. salud.gob.mx.
2. Dirección General de Información en Salud (DGIS). Base de datos de egresos hospitalarios por morbilidad en Instituciones Públicas, 2004-2007. Sistema Nacional de Salud (SINAIS). Available at: http://www.sinais.salud.gob.mx.
3. Villalpando S, De la Cruz V, Rojas R, Shamah T, Ávila M, Gaona B, et al. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey. Salud Pública Mex 2010;52(Suppl):S19.
4. Surendiran A, Pradhan SC, Agrawal A, Subrahmanyam DK, Rajan S, Anichavezhi D, et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol 2011;67: 797-801.
5. Martínez MA, Kravzov J, Moreno MR, Rubio C, Skromne D, Rivas M, et al. Diabetes mellitus type 2: sales of oral hypoglycemic agents and costs of the pharmacological treatments in Mexico. Rev Mex Cienc Farm 2007;38: 23-33.
6. Díaz C, Martínez MA, Kravzov J, Cárdenas MR, Moreno C, Martínez JM. Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City. Clinicoecon Outcomes Res 2012;4: 57-65.
7. Hatta F, Teh L, Hellden A, Hellgren K, Roh H, Salleh M, et al. Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A >T and the losartan metabolism phenotype in Swedes. Eur J Clin Pharmacol 2012;68: 1033-42.
8. Dorado P, Sosa M, Peñas M, Alanis R, Wong L, Licinio J, et al. CYP2C9 allele frequency differences between populations of Mexican Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics J 2011;11: 108-12.
9. Ley General de Salud, Diario Oficial de la Federación, 7 de febrero de 1984:1-148. Available at: http://www.diputados.gob. mx/LeyesBiblio/pdf/142.pdf.
10. Reglamento de la Ley General de Salud en Material de Investigación para la Salud, Diario Oficial de la Federación, 6 de enero de 1987:1-24. Available at: http://www.salud.gob.mx/ unidades/cdi/nom/compi/rlgsmis.html.
11. Reglamento de la Comisión Federal para la Protección contra Riesgos Sanitarios, Diario Oficial de la Federación, 13 de abril de 2004:1-15. Available at: http://www.diputados.gob.mx/ LeyesBiblio/regla/29.PDF.
12. Rubí R, Martínez G, Muñoz JF, González A, Cerda RM, Anaya M, et al. Pre-Hispanic mesoamerican demography approximates the present-day ancestry of mestizos throughout the territory of Mexico. Am J Phys Anthropol 2009;139: 284-94.
13. Martínez M, Beuten J, Leach R, Parra E, Cruz M, Rangel H, et al. Ancestry informative markers and admixture proportions in northeastern Mexico. J Hum Genet 2009;54: 504-9.
14. Jiménez G, Silva I, Hidalgo A, March S. Genomic medicine in Mexico: initial steps and the road ahead. Genome Res 2008;18: 1191-8.
15. Mendoza R, Wan Y, Poland R, Smith M, Zheng Y, Berman N, et al. CYP2D6 polymorphism in Mexican American population. Clin Pharmacol Ther 2001;70: 552-60.
16. Yang M, Tsuang J, Yvonne Y. A haplotype analysis of CYP2E1 polymorphisms in relation to alcoholic phenotypes in Mexican Americans. Alcohol Clin Exp Res 2007;31: 1991-2000.
17. Lucas D, Ferrab R, Gonzalez E, Bodenez P, Albores A, Imannob R, et al. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 1999;9: 377-88.
18. Sosa-Macias M, Lazalde BP, Galaviz C, Rangel H, Salazar J, Martínez VM, et al. Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico. Pharmacogenomics J 2013;1-6.
19. González H, Romero EM, Peregrina A, Chavez T, Escobar E, Lozano F, et al. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans. J Clin Pharmacol 2003;43: 1211-5.
20. Lares I, Sosa M, Elizondo G, Flores C, Flores J, Bradley F. Phenotypical expression of CYP2D6 in Amerindians of Tepehuano origin from Durango, Mexico. Proc West Pharmacol Soc 2006;48: 102-7.
21. Luo H, Gaedigk A, Aloumanis V, Wan Y. Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur J Clin Pharmacol 2005;61: 797-802.
22. Contreras A, Monge T, Alfaro L, Hernández S, Miranda H, Carrillo K, et al. Resequencing, haplotype construction and identification of novel variants of CYP2D6 identification of novel variants of CYP2D6 in Mexican Mestizos. Pharmacogenomics 2011;12: 745-56.
23. Sosa M, Elizondo G, Flores C, Flores J, Bradley F, Alanis R, et al. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. J Clin Pharmacol 2006;46: 527-36.
24. Sosa M, Dorado P, Alanis R, Llerena A, Lares I. Influence of CYP2D6 deletion, multiplication, -1555584C-G, 31 G-A and 2988 G-A gene polymorphism on dextromethorphan metabolism among Mexican Tepehuanos and Mestizos. Pharmacology 2010;86: 30-6.
25. López, M, Guerrero J, Jung H, Alonso M. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. Eur J Clin Pharmacol 2005;61: 749-54.
26. Salazar J, Torres LA, Martínez G, Rubí R, Sosa M, Muñoz JF, et al. Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and Western Mestizos from Mexico. Genet Test Mol Biomarkers 2012;22.
27. Luo H, Poland R, Lin K, Yvonne Y. Genetic polymorphism of cytochrome P450 2C19 in Mexicans Americans: a cross-ethnic comparative study. Clin Pharmacol Ther 2006;80: 33-40.
28. Reyes O, Lares I, Sosa M, Vega L, Albores A, Elizondo G. A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations. Pharmacology 2008;81: 97-103.
29. Llerena A, Dorado P, O'Kinwan F, Jepson R, Licinio J, Wong M. Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J 2004;4: 403-6.
30. Díaz R, Cornejo J, Ramos M, Estrada J, Morales O, Reyes R, et al. Genotype and phenotype of NAT2 and the occurrence of adverse drug reactions in Mexican individuals to an isoniazidbased propylactic chemotherapy for tuberculosis. Mol Med Rep 2008;1: 875-9.
31. Taja L, Agúndez JA, Miguez C, Chavez A, Dueñas A. Arylamine N-acetyl transferase 2 genotypes in a Mexican population. Genet Mol Res 2012;11: 1082-92.
32. Montero R, Araujo A, Carranza P, Mejía C, Serrano L, Albores A, et al. Genotype frequencies of polymorphic GSTM1, GSTT1 and cytochrome P450 CYP1A1 in Mexicans. Hum Biol 2007;79: 299-312.
33. Poland R, Lin K, Nuccio C, Wilkinson G. Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans. Clin Pharmacol Ther 2002;72: 288-93.
34. López M, Dorado P, Ortega A, Peñas E, Monroy N, Silva I, et al. Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. Mol Biol Rep 2013;40: 3187-92.
35. Gómez O, Sesma S, Becerril V, Knaul F, Arreola H, Frenk J. Mexico Health System. Salud Pública de México 2011;53(Suppl):S220. Available at: http://bvs.insp.mx/rsp/articulos/articulo- e4.php?id=002625.
36. Breimer D, Schellens J. A cocktail strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci 1990;11: 223-5.
37. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in human and their simultaneous use in the cocktail approach. Clin Pharmacol Ther 2007;81: 270-83.
38. Frye R, Matzke G, Adedoyin A, Porter J, Branch A. "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997;365-76.
39. Christensen M, Anderson K, Dalén P, Mirghani R, Muirhead G, Nordmark A, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003;73: 517-28.
40. Ryu J, Song I, Sunwoo Y, Shon J, Liu K, Cha I, et al. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther 2007;82: 531-40.